Agilent stock analysis
Agilent (0HAV) Share Price & Analysis
0HAV Stock Chart & Stats
- Day’s Range
- $170.00 - $175.75
- 52-Week Range
- $107.66 - $184.99
- Previous Close
- $173.64
- Volume
- N/A
- Average Volume (3M)
- 1,054
- Market Cap
- $48.78B
- Enterprise Value
- $41.35B
- Total Cash (Recent Filing)
- $1.76B
- Total Debt (Recent Filing)
- $3.95B
- Price to Earnings (P/E)
- 34.2
- Beta
- 0.93
- Next Earnings
- Nov 23, 2026 (Est.)
- EPS Estimate
- 1.73
- Last Dividend Ex-Date
- Oct 06, 2026
- Dividend Yield
- 0.59%
Bulls Say, Bears Say
Bulls Say
Raised FY26 Growth Outlook
The higher FY26 outlook indicates that management sees sustained demand across instruments, software, services, and end markets rather than relying solely on a temporary quarterly benefit. Continued revenue and EPS growth should support reinvestment and strengthen Agilent’s operating scale over the next several quarters.
Installed-base Recurring Revenue Model
Agilent’s installed-base model creates repeat demand beyond the initial instrument sale through consumables, maintenance, software, and workflow integration. This recurring component can deepen customer relationships, raise switching costs, and make revenue more resilient as instruments remain in laboratory operations.
Strong Cash Generation
High free-cash-flow generation gives Agilent flexibility to fund research, product launches, capital returns, and debt management without relying heavily on external financing. Strong conversion also supports the durability of reported profitability, although operating-cash timing can still create periodic volatility.
Bears Say
Gross-margin Compression
The sharp gross-margin decline suggests that mix, pricing, or cost pressures have weakened the economics of Agilent’s offerings compared with prior periods. If the lower margin persists, it could constrain operating leverage, reduce earnings upside, and make future growth more dependent on execution and cost control.
Rising Debt Reduces Flexibility
Higher debt increases Agilent’s fixed financial commitments and reduces flexibility if laboratory capital spending or end-market demand weakens. Although leverage remains moderate, continued debt growth could compete with investment and shareholder returns while increasing sensitivity to refinancing and interest-cost pressures.
Capital-spending And Service-timing Exposure
Agilent’s model remains exposed to customers delaying instrument purchases during weaker capital-spending periods, while service monetization does not immediately offset slower placements. The stated 12–18 month conversion lag can therefore create uneven revenue progression and delay recurring-service benefits after demand improves.
Agilent News
0HAV FAQ
What was Agilent’s price range in the past 12 months?
What is Agilent’s market cap?
When is Agilent’s upcoming earnings report date?
How were Agilent’s earnings last quarter?
Is Agilent overvalued?
Does Agilent pay dividends?
What is Agilent’s EPS estimate?
How many shares outstanding does Agilent have?
What happened to Agilent’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Agilent?
What is the TipRanks Smart Score and how is it calculated?
Agilent Stock Smart Score
Company Description
Agilent
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell
- Employees
- 18,200
- Website
- www.agilent.com
- Address
- 5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, US
Agilent (0HAV) Earnings & Revenues
0HAV Company Deck
0HAV Earnings Call
Earnings Call SentimentPositive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.
View all GB:0HAV earnings summaries0HAV Net sales Breakdown
- 39.23% Life Sciences and Diagnostics Markets
- 41.85% Agilent CrossLab
- 18.91% Applied Markets
0HAV Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 6 | 0 | 6 |













